SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52153 679 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
51878CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First GeneFrank Sully111/16/2021
51877Caribou Bioscience EPS misses by $0.40, beats on revenue Nov. 09, 2021 4:55 PM Frank Sully-11/12/2021
51876CRISPR Therapeutics (NASDAQ:CRSP) Posts Quarterly Earnings Results, Beats EstimaFrank Sully-11/7/2021
51875I just listened to the conference call for ALNY. I can see two reasons for the A.J. Mullen-10/28/2021
51874Decent but unspectacular results from Alnylam, and announces the CEO's replaA.J. Mullen-10/28/2021
51873Crispr Therapeutics: The Future Of Gene Therapy Oct. 15, 2021 CRISPR TherapeutFrank Sully110/15/2021
51872CRISPR Therapeutics on the rise amid takeover chatter Oct. 14, 2021 By: Dulan Frank Sully-10/14/2021
51871Frank, if that's your decision, consider trading out-of-hours if you can. SA.J. Mullen-10/12/2021
51870CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTFrank Sully-10/12/2021
51869My holding in CRSP is relatively small but I’m planning to increase it 50% tomorFrank Sully-10/12/2021
51868I just added 10% to my longterm holding of CRSP in after hours trading. Paid $9A.J. Mullen110/12/2021
51867CRSP stock down 10% after hours Crispr Stock Follows Allogene's Path And DiFrank Sully-10/12/2021
51866Allogene study halt drags down peers on safety concerns Caribou currently down Frank Sully-10/8/2021
51865Their tech looks very impressive indeed. The valuation, I don't know either,nigel bates-10/1/2021
51864I think Oxford Nanopore is very interesting. They are set to challenge the domiA.J. Mullen-10/1/2021
51863New to the site and I want to get some feedback on a stock I've been lookingAdam H-10/1/2021
51862Not a clue, Nigel.Frank Sully-9/30/2021
51861Sequencing company Oxford Nanopore listed on the London stockmarket today at a cnigel bates-9/30/2021
51860One of the better efforts, apparently. Any idea when it might IPO ?nigel bates-9/30/2021
51859What Drives Newly Minted Crispr Unicorn Mammoth Biosciences [graphic] John CumFrank Sully-9/29/2021
51858Crispr Is Still Promising, Even If Editas’s Experiment Falls Short By Max NisenFrank Sully-9/29/2021
51857A Pivotal Moment for CRISPR in the Gene Editing Journey Published: Aug 04, 202Frank Sully19/27/2021
51856Why Cathie Wood Is Buying 2 Gene-Editing Stocks but Selling Another Wood is folFrank Sully-9/27/2021
51855UK approves Europe’s first field trials of Crispr-edited wheat [graphic] BY JFrank Sully19/27/2021
51854RNA-targeting enzyme expands the CRISPR toolkit by Jennifer Michalowski , MassFrank Sully19/27/2021
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News